...
首页> 外文期刊>Arthritis research & therapy. >Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents
【24h】

Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents

机译:免疫球蛋白G4相关性涎腺炎的治疗:糖皮质激素治疗与类固醇保护剂联合治疗的结果

获取原文
           

摘要

Immunoglobulin G4-related sialadenitis (IgG4-RS) is a newly recognized immune-mediated systemic disease. Despite its good response to steroid therapy, its treatment protocol is not standardized and the long-term outcome is controversial. The study was conducted to determine the short-term and long-term outcomes of IgG4-RS patients treated with glucocorticoids and steroid-sparing immunosuppressive agents, to analyze secretory function, serological and radiological changes in salivary glands and to assess the usefulness of serum IgG4 level as an indicator of disease activity. IgG4-RS patients who were treated for more than 3?months were enrolled. Serological tests, salivary gland function assessment and computed tomography (CT) were performed before treatment and during follow up. The treatment outcomes in the short and the long term were evaluated, and the relationship between serum IgG4 level and salivary gland volume was analyzed. Glucocorticoids were used in all 43 patients and steroid-sparing immunosuppressive agents in 38 patients (88.4%). The follow-up period was 24.6?±?14.9?months. Clinical remission was achieved in all patients after induction therapy. During short-term observation, salivary gland secretion significantly increased, and the serum IgG4 levels, the volumes and CT values of submandibular and parotid gland decreased significantly (P?
机译:免疫球蛋白G4相关性涎腺炎(IgG4-RS)是一种新近公认的免疫介导的全身性疾病。尽管其对类固醇疗法反应良好,但其治疗方案尚未标准化,长期结果仍存在争议。这项研究旨在确定接受糖皮质激素和类固醇免疫抑制剂治疗的IgG4-RS患者的短期和长期结局,分析唾液腺的分泌功能,血清学和放射学变化,并评估血清IgG4的有效性水平作为疾病活动的指标。纳入治疗时间超过3个月的IgG4-RS患者。在治疗前和随访期间进行血清学检查,唾液腺功能评估和计算机断层扫描(CT)。评价短期和长期的治疗效果,并分析血清IgG4水平与唾液腺体积之间的关系。在所有43例患者中均使用糖皮质激素,在38例患者中(88.4%)使用了类固醇激素免疫抑制剂。随访时间为24.6±14.9个月。诱导治疗后所有患者均达到临床缓解。在短期观察中,唾液腺分泌显着增加,血清IgG4水平,下颌下腺和腮腺的体积和CT值均显着下降(P <0.001)。长期来看,常规治疗组中55.个月内有32.5%的患者复发,而所有7例不规则治疗的患者均复发。但是,类固醇单一疗法和联合疗法组之间的无复发生存曲线没有显着差异(P = 0.566)。颌下腺,泪腺,舌下腺,鼻腔和鼻旁腔通常是复发性器官。在临床稳定的患者中,在55个月内有54.9%的患者发生了血清学上不稳定的状况,因此进行了药物调整。颌下腺和腮腺的体积变化与血清IgG4水平和随访时间有关(R2调整后的α=?0.905,P?<0.0001,R2调整后的?=?0.9334,P?<0.0001)。糖皮质激素和类固醇保护剂的组合可有效治疗IgG4-RS,恢复唾液腺功能。血清IgG4水平可以预测疾病活动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号